News
Beijing reports growth in drug trial capacity
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
The Beijing Municipal Health Commission said on 14 August 2026 that drug trials led by Beijing institutions rose from 583 in 2020, 19.1 percent of the national total, to 1,077 in 2025, or 27.4 percent, citing the Centre for Drug Evaluation’s annual report on drug registration trials in China. It also reported that Beijing institutions led 64 of 149 cell and gene therapy trials in China in 2025, and 26 of 95 paediatric trials.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier B — headline, our own summary and a link back only; no full-text copy.